Mobile

A multi-national, open-labelled, randomised, parallel group, 4 week run-in and 26 weeks treat-to-target comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily both in c...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003288-29

A multi-national, open-labelled, randomised, parallel group, 4 week run-in and 26 weeks treat-to-target comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily both in combination with metformin and glimepiride in insulin naïve subjects with type 2 diabetes. Trial Phase: 4

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate if biphasic insulin aspart (BIAsp) 30 once daily (OD) in combination with metformin and glimepiride is non-inferior and superior in the event of non-inferiority, compared with insulin glargine OD in combination with both metformin and glimepiride with respect to glycaemic control, as measured by HbA1c after 26 weeks of treatment in subjects with type 2 diabetes, failing on oral anti-diabetic drugs (OADs).

Critère d'inclusion

  • Type 2 Diabetes

Liens